GLYC (GlycoMimetics) 3-Year Sharpe Ratio : 0.41 (As of Jul. 04, 2025)

View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-07-04), GlycoMimetics's 3-Year Sharpe Ratio is 0.41.

Competitive Comparison of GlycoMimetics's 3-Year Sharpe Ratio

For the Biotechnology subindustry, GlycoMimetics's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlycoMimetics's 3-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's 3-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

GlycoMimetics 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.

GlycoMimetics (NAS:GLYC) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

GlycoMimetics 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

GlycoMimetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » 3-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

GKO:Germany GKO:Germany

Address

P.O. Box 65, Monrovia, MD, USA, 21770

Website

https://www.glycomimetics.com

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

Executives

Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Edwin Rock	officer: Chief Medical Officer	9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn	officer: CFO	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius	director	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson	officer: SVP & Chief Commercial Officer	9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath	officer: SVP and Chief Business Officer	9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities Advisors, Llc	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting	10 percent owner	CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell	10 percent owner
Harout Semerjian	director, officer: Chief Executive Officer	300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950